AML ANTIGENS AND USES THEREOF

Abstract

The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.

Claims

1. A synthetic or recombinant nucleic acid molecule, or a functional equivalent thereof, encoding a CD43 peptide for AT14-013 antibody binding, said peptide comprising the amino acid sequence of SEQ ID NO. 3 and having an AML-specific glycosylation pattern or an MDS-specific glycosylation pattern.

2. The nucleic acid molecule or functional equivalent of claim 1, wherein said nucleic acid molecule or functional equivalent has been codon optimized for a non-human cell, for instance for a non-human producer cell.

3. The nucleic acid molecule or functional equivalent of claim 1, wherein said nucleic acid molecule or functional equivalent comprises a chain comprising non-natural nucleotides, modified nucleotides and/or non-nucleotide building blocks which exhibit the same function as natural nucleotides.

4. The nucleic acid molecule or functional equivalent of claim 1, wherein said nucleic acid molecule or functional equivalent comprises a DNA/RNA helix, peptide nucleic acid (PNA), locked nucleic acid (LNA) and/or a ribozyme.

5. The nucleic acid molecule or functional equivalent of claim 1, wherein said nucleic acid molecule or functional equivalent comprises cDNA.

6. A vector comprising the nucleic acid molecule or functional equivalent of claim 1.

7. A method for producing, binding, detecting and/or obtaining an immune cell and/or an antibody, or a functional part or functional equivalent thereof, characterized in that a nucleic acid molecule or functional equivalent of claim 1 is used.

8. The method of claim 7, for inducing, binding, detecting and/or obtaining an immune cell and/or an antibody, or a functional part or functional equivalent thereof, that is able to specifically bind myeloproliferative or lymphoproliferative cells.

9. The method of claim 8, wherein said myeloproliferative cells are acute myeloid leukemia (AML) cells or myelodysplastic syndrome (MDS) cells or chronic myeloid leukemia (CML) cells.

10. The method of claim 7, wherein said antibody has antibody-dependent cell-mediated cytotoxicity (ADCC) inducing activity and/or complement-dependent cytotoxicity (CDC).

11. A gene delivery vehicle comprising the nucleic acid molecule or functional equivalent of claim 1.

12. A host cell comprising the nucleic acid molecule or functional equivalent of claim 1.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0116] FIG. 1A and FIG. 1B Sequence of AT14-013 (2K23-1K13) including the variable heavy and light chain sequences and the CDR sequences of the antibody.

[0117] FIG. 2. Binding of AT14-013 to AML cell lines and freshly isolated primary AML blasts from newly diagnosed patients. FAB: French-American-British classification of AML (Bennett et al. 1976).

[0118] FIG. 3. AT14-013 binds to AML cell lines and primary isolated AML cells. Representative examples of binding of AT14-013 derived from patient 101 to the AML cell lines Kasumi3, SH-2, Molm13 and THP-1 and to primary leukemic blasts isolated from newly diagnosed AML patients (FAB classification M0-M5). An in-house produced human antibody specific for influenza was used as a negative control (grey filled histograms).

[0119] FIG. 4. AT14-013 also binds to leukemic blasts from patients with high-risk myelodysplastic syndrome (MDS/RAEB I and II) and blast crisis chronic myeloid leukemia (CML). Depicted are representative examples; indicated are patient identification codes except K562 which is a CML cell line. An in-house produced human antibody against influenza was used as a negative control (grey filled histograms). * BL-060: biphenotypic leukemia, responding well to AML treatment.

[0120] FIG. 5A, FIG. 5B, and FIG. 5C. AT14-013 does not bind to non-myeloid cells. (a) FIG. 5A AT14-013 did not bind to healthy PBMCs, T cells (CD3+), B cells (CD19+), non activated monocytes (CD14+) or primary isolated thymocytes (except for a small population of myeloid cells that are present in fetal thymus). (b) FIG. 5B AT14-013 also did not bind primary isolated B- or T-ALL cells, lymphoma's or multiple myeloma. (c) FIG. 5C AT14-013 also did not bind colon carcinoma cell lines or primary isolated cells from patients with colon carcinoma (Colon CA) or healthy colon or ileum.

[0121] AT14-013 did bind to granulocytes (FIG. 5A) and human melanoma cell lines (FIG. 5C). An in-house produced human antibody against influenza was used as a negative control (grey filled histograms).

[0122] FIG. 6. CDC and ADCC. Calcein labeled THP-1 cells were incubated with AT14-013 and rabbit serum complement. Living cells were identified as calcein+, dapi− cells. With our bead based assay the amount of dead cells could then be calculated as a measure of complement dependent cell death (CDC). Incubation of THP1 cells with CD33 did not induce CDC (left panel). AT14-013 is also able to induce antibody dependent cell cytotoxicity (ADCC) in a Jurkat reporter system with the AML cell line SH-2 or freshly isolated leukemic blasts as target cells (right panel).

[0123] FIG. 7. Target identification of AT14-013: immunoprecipitation (IP). IP with biotin-labeled (via a sortase tag) AT14-013 of THP1 cell lysates yielded a ˜140 kDa band on an Imperial Coomassie stained gel. The band is specific as it is not seen in the AT10-002 IP of THP1 lysate or in the Jurkat lysate IP. The band was excised from gel and the target indentified as CD43 by mass spectrometry.

[0124] FIG. 8. Target confirmation of AT14-013. THP-1 and Molm13 lysates were immunoprecipitated with AT14-013 or with the influenza-specific antibody AT10-002. Western blot analysis with mouse-anti-CD43 (clone Mem59) confirmed CD43 as the binding target of AT14-013.

[0125] FIG. 9A, FIG. 9B, FIG. 9C, and FIG. 9D. AT14-013 binds to a unique CD43 epitope. (a) FIG. 9A THP-1 cells were stained with the commercially available CD43 specific antibodies DF-T1, 84-3C1, L10 and Mem59 and with AT14-013. All antibodies bound to the membrane of THP-1 cells. (b) FIG. 9B AT14-013 has a different binding profile compared to commercially available CD43-specific antibodies. In Kim ea, (Kim et al. 2014), binding of commercially available CD43 antibodies YGS, 2C8, 8E10 and DFT-1 to various cell lines is summarized. We compared binding of AT14-013 to the same cell lines and found a different binding pattern. (c) FIG. 9C A competition experiment with AT14-013 and commercially available CD43 specific antibodies was performed as indicated. Briefly, THP-1 cells were incubated with indicated antibodies at increasing concentrations, after which the possibly competing antibody (referred to as ‘competing antibody’) was added. AT14-013 binding to THP-1 target cells was not affected by pre-incubation of the cells with commercially available CD43 antibodies, while these commercially available CD43 antibodies did inhibit each other's binding to THP-1 cells. Results are shown for experiments wherein AT14-013 or 84-3C1 was the “competing antibody”. (d) FIG. 9D Summary of competition experiments. AT14-013 does not compete with commercially available CD43 antibodies for binding to THP-1, indicating that AT14-013 binds a different epitope.

[0126] FIG. 10. Deglycosylation of THP-1 cells with neuraminidase (sialidase) removes the sialic acids from the cell membrane. “No” indicates no neuraminidase treatment and “1:20” and “1:200” indicates the neuraminidase dilution. Antibodies AT14-013, Mem59, DF-T1 and 84-3C1 lost binding to THP-1 cells after neuraminidase treatment of these cells. Clone L10 is not binding to a sialilated epitope of CD43, as neuraminidase treatment of THP-1 cells did not affect binding of this antibody to its target cells.

[0127] FIG. 11A and FIG. 11B. CD43 truncated variants map the epitopes of commercially available antibodies DF-T1 and MEM59. FIG. 11A Immunoblot of HEK293T cells expressing truncated variants of CD43 probed with anti-CD43 directed towards the intracellular C-terminal tail of the protein. FIG. 11B Immunostaining of the same blot with CD43 specific antibodies MEM59 (upper panel) and DF-T1 (lower panel) revealed the presence of their epitope in region ‘C’ (amino acids 59-82).

[0128] FIG. 12A, FIG. 12B, and FIG. 12C. Immunoprecipitation of CD43 truncated variants from THP1 cells identifies the AT14-013 epitope. FIG. 12A Immunoblot of input lysates of sorted CD43 truncated variant overexpressing THP1 cells probed with anti-Flag antibody. PonseauS staining demonstrates equal loading of samples. All mutant proteins are expressed. FIG. 12B Anti-Flag immunoblot of eluted immunoprecipitations of THP1 variant cell lines with AT14-013 reveals binding to mutants A-F and no binding to mutants H-J, defining the epitope. FIG. 12C Immunoblot with anti-CD43 cytoplasmic tail binding antibody (Novus) showing endogenous immunoprecipitated CD43 in all samples as well as staining of truncated variants.

[0129] FIG. 13. Amino acid sequence of CD43 (genbank CCDS10650.1). The signal peptide, AT14-013 epitope, transmembrane domain and intra- and extracellular domains are indicated.

[0130] FIG. 14A and FIG. 14B. Binding of AT14-013 to other AML blasts. Binding of AT14-013 to freshly isolated primary AML blasts (CD45dim) from newly diagnosed patients. An in-house produced human antibody specific for influenza was used as a negative control. For the commercial mouse anti CD43 antibodies a mouse anti CMV was used as control. WHO: Swerdlow S. H. WHO classification of Tumours of Haematopoietic and Lymphoid tissues (2008). CD43+ T cells and tonsil cells were used as extra control for the assay. AT14-013 does not bind to these healthy cells.

[0131] (% gated=−; <10%, +; 10-25%, ++; 25-50%, +++; 50˜75%, ++++; 75-100%)

[0132] FIG. 15A and FIG. 15B. ADCC and CDC. FIG. 15A AT14-013 (open squares) is capable of inducing antibody dependent cell mediated cytotoxicity (ADCC) on the AML cell line SH-2 with PBMCs in an effector target ratio of 50:1. Living cells were identified as calcein+, dapi− cells. With our bead based assay the amount of dead cells could then be calculated. Incubation of SH2 cells with AT10-002 did not induce ADCC (black dots). The calculated EC50 for AT14-013 is 0.16 ug/ml. FIG. 15B Calcein labeled SH-2 cells were incubated with AT14-013 (open squares) or AT10-002 (black dots) and rabbit serum complement. Living cells were identified as calcein+, dapi− cells. Incubation of SH2 cells or AML blasts with AT10-002 did not induce CDC (black dots). The calculated EC50 for AT14-013 was 1.86 ug/ml.

[0133] FIG. 16A and FIG. 16B. FIG. 16A Anti-Flag immunoblot of eluted immunoprecipitations of THP1 variant cell lines with AT14-013 reveals binding to mutants A-F2, binding to a lesser extent to G, and no binding to mutants H-J. FIG. 16B Immunoblot with anti-CD43 cytoplasmic tail binding antibody (Novus) showing endogenous immunoprecipitated CD43 in all samples as well as staining of truncated variants. This control confirms that the immunoprecipitation was successful for all samples shown.

[0134] FIG. 17.

[0135] a) Treatment of mice engrafted with SH-2 AML cells leads to a tumor growth inhibition of 90.3% as measured at the sacrifice by whole body measurement (p<0.001, repeated ANOVA).

[0136] b) The number of AML cells, measured by the number of photon per minute (cpm) exhibits a strong decrease in all the organs measured (p=0.0011, repeated 2way ANOVA).

[0137] c) Evaluation of the number of tumor cells by FACS in the bone marrow and the liver (p=0.0017, 2way ANOVA).

[0138] FIG. 18. Representative examples of binding of AT14-013 to fetal CD34+ hematopoietic stem cells (HSC) but not to fetal CD34+CD38+ progenitor cells or fetal CD34-CD38-mature cells. Grey filled histograms: control antibody AT10-002 directed against influenza, described in WO 2013/081463.

[0139] FIG. 19. AT14-013 reacts with autologous leukemic stem cells.

[0140] AML blasts of donor #101 (the same donor from whom the B cells producing AT14-013 were obtained) were stained with AT14-013 and with antibodies specific for CD34 and CD38, and with an antibody against CD45 (BD, cat 348815) to distinguish the general blast population (CD45 dim) from healthy cells in the bone marrow and analyzed by flow cytometry.

EXAMPLES

Example 1

[0141] Material & Methods

[0142] Patient and Healthy Human Materials

[0143] Study protocols were approved by the Medical Ethical Committee of the Academic Medical Centre. All participants signed informed consent. Participants included healthy individuals and patients with hematologic malignancies recruited from our clinic that donated peripheral blood and/or bone marrow.

[0144] Generation of AML-Specific Clone AT14-013

[0145] As described in Example 2 of WO 2015/093949, transduced naïve and memory IgG B cells of AML patient 101, immortalized by introduction of Bcl6 and Bcl-xL as described previously (Kwakkenbos et al., Nat Med 2010 and Example 1 of WO 2015/093949), were seeded at a concentration of 20 or 40 cells per well (hereafter named microcultures) and expanded with IL-21 and CD40L. Supernatants of expanded B cell microcultures were then screened for antibody binding to AML cell lines (amongst others THP-1, MonoMac6), and to liver and colon cell lines, by FACS, using human IgG H+L AF647 (Life Technologies) or human-IgG-PE (Southern Biotech) as a secondary antibody. Several in-house generated antibodies were used as negative control antibodies, such as anti-CD30 (expressed on activated B and T lymphocytes), anti-CD33 (expressed on monocytes, myeloid progenitor cells and myeloid leukaemias), D25 (against RSV; described in WO 2008/147196) and AT10-002 (against influenza; described in WO 2013/081463). Microcultures binding to AML cell lines but not to liver and colon cell lines were selected and seeded at a concentration of 1 cell/well and their supernatants tested again for specificity for AML cell lines. Clones with supernatants specifically binding AML cell lines and not liver or colon cell lines, or healthy PBMC and bone marrow were selected for sequencing. Clones were expanded under normal culture conditions in the presence of FBS IgG low serum (Hyclone) and antibodies purified from the supernatants of these cultures as described below for the recombinant antibodies. The recombinant antibodies were then again tested for specific binding. One of the obtained AML-specific antibodies was AT14-013. The discovered AT14-013 antibody was additionally tested on many freshly isolated blasts of newly diagnosed AML patients (FAB M0-M5) for binding, using human IgG H+L AF647 (Life Technologies) as a secondary antibody.

[0146] Cloning of AML-Specific Antibody AT14-013

[0147] As described in Example 1 of WO 2015/093949, to produce recombinant antibody we isolated total RNA with the RNeasy® mini kit (Qiagen), generated cDNA, performed PCR and cloned the heavy and light chain variable regions into the pCR2.1 TA cloning vector (Invitrogen). To rule out reverse transcriptase or DNA polymerase induced mutations, we performed several independent cloning experiments. To produce recombinant mAb we cloned heavy and light variable regions of each antibody in frame with human IgG1 and Kappa constant regions into a pcDNA3.1 (Invitrogen) based vector and transiently transfected 293T cells. We purified recombinant antibodies from the culture supernatant with Protein A or G, depending on the Ig subtype of the clone.

[0148] CDC and ADCC

[0149] To quantify complement dependent cell death (CDC) of target cells induced by AML-specific antibody AT14-013 we used a FACS-based leukemia cell lysis assay. THP-1 cells were incubated with 2 μM Calcein AM (Becton Dickinson) for 30 minutes at 37° C. Calcein labeled THP-1 cells were incubated together with antibodies and rabbit serum complement for 4 hours at 37° C. FACS calibration beads (Accudrop Fluorescent Beads, BD Biosciences) were added to the cells in a 50/50 ratio after which a standard amount of beads was acquired with FACS. As an equal assay volume was ascertained by the calibration beads, the amount of dead cells was calculated as: 100−((Dapi negative, Calcein AM positive cells in respective treatment/Dapi negative, Calcein AM positive cells in control)×100). For the antibody dependent cell mediated cytotoxicity (ADCC) we generated a read-out system with Jurkat cells that were stably transduced with NFAT(6×)-IL2 (minimal promoter)-GFP and CD16a (FcR-IIIa). Activation of the CD16a receptor by bound antibody in this system activates NFAT which induces GFP expression that is then used as a read-out to quantify effector cell activation. AML cells (target cells) were incubated with antibodies and mixed with Jurkat cells (effector cells) that were stained with Calcein AM as described above. Effector: target ratio was 1:1.

[0150] AT14-013 Target Identification and Validation

[0151] THP-1 cells were lysed (0.5% Triton X114 (Sigma), 150 mM NaCl, 10 mM Tris-HCL pH7.4, 1.5 mM MgCl2 supplemented with protease and phosphatase inhibitors (Roche)) and precleared with an irrelevant antibody (in-house generated RSV antibody D25), Protein-G and Streptavidin beads (Pierce) to remove non specific binding proteins. Precleared lysate was then incubated with bead-bound AML-specific antibodies or with the influenza specific antibody AT10-002 as a negative control (3 hrs at 4° C.). Antibody-incubated beads were washed five times in lysis buffer supplemented with 0.5% Deoxycholate and 0.1% SDS, bound proteins were eluted from the beads (0.1M Glycine pH10.5, 150 mM NaCl, 1% Triton X100, 1 mM EDTA) and then run on an SDS-PAGE gel. 85% of IP samples was run on SDS-PAGE and stained with Imperial protein stain (Pierce) to stain total proteins and excise specific bands for Mass Spectrometry. The rest of the IP samples were run on SDS-PAGE and transferred to PVDF membrane (Bio-RAD) for immunoblotting. The blot was stained with Ponseau S to reveal total protein and blocked with BSA, then incubated with mouse-anti-CD43 (clone MEM-59, Abcam) for Western blot analysis.

[0152] Epitope Mapping: Competition

[0153] THP-1 cells were pre-incubated for 60 minutes on ice with AT14-013 and the commercially available CD43 antibodies: mouse anti human CD43 PE (Ebioscience; clone 84-3C1), mouse anti human CD43 FITC (Invitrogen; clone L10), mouse anti human CD43 FITC (Abcam; clone MEM-59), mouse anti human CD43 unlabeled (Abcam; clone MEM-59), mouse anti human CD43 unlabeled (Thermo Scientific; clone DF-T1). The maximum blocking antibody concentration was 1 ug/ml. Next, the competing antibody was added with a final concentration of 1 ug/ml. With this step, the final concentration of the blocking antibodies is 2 ug/ml. Cells were incubated for 30 minutes on ice, after which dapi (Sigma) was added to exclude dead cells from the analyses. Samples were analyzed by flow cytometry.

[0154] Epitope Mapping: Deglycosylation

[0155] THP-1 cells were incubated with neuraminidase (Roche; dilution 1:20 or 1:200) for 60 minutes at 37° C. to remove sialic acids from CD43 (de Laurentiis et al. 2011). Cells were then washed, blocked in 60% normal goat serum and incubated with AT14-013 and the commercially available CD43 antibodies DF-T1, 84-3C1, L10 and MEM-59 as described above. To allow comparison of cell staining with different fluorochromes, binding to untreated cells (no neuraminidase) was set to 1. Depicted in FIG. 10 is fold increase/decrease of binding to neuraminidase treated cells.

[0156] Epitope Mapping: CD43 Truncated Variants.

[0157] CD43 cDNA was obtained from Geneart (Life Technologies) and adapted to contain a 3×FLAG tag in-frame on either C- or N-terminus (C-terminal to the signal peptide, comprising the first 19 amino acids of CD43). The cDNA was cloned into the pHEF-TIG third-generation lentiviral vector containing an IRES-GFP 3′ of the CD43 cDNA; VSV-G lentiviral particles were produced in HEK293T cells. THP1, MOLM and other cells were transduced with these viruses in the presence of retronectin and sorted for GFP to obtain a pure population of CD43 overexpressing cells. Truncated CD43 variants were constructed by PCR-cloning of the CD43 C-terminal FLAG-tagged cDNA to contain the signal peptide (AA 1-19) followed by the wild-type full length extracellular sequence (variant A: S20-P400, followed by 3×FLAG: DYKDHDGDYKDHDIDYKDDDDK) or truncated extracellular sequences (variant B-J). B: 31-400; C: 59-400; D: 82-400; E: 112-400; F: 133-400; G: 166-400; H: 184-400; I: 202-400; J: 220-400 (the transmembrane domain starts at AA 255. These variants were expressed in THP1 cells by lentiviral transduction and GFP sorted. Sorted cells were lysed and immunoprecipitated with AT14-013 and control as described above. Eluted IP samples were run on SDS-PAGE and immunoblotted with anti-FLAG-HRP (Sigma) to reveal binding.

[0158] Results

[0159] AT14-013 Specifically Binds to AML Cells

[0160] In this Example we identify the target of the AML specific antibody AT14-013 that was recently developed in our laboratory (WO 2015/093949 and 1A/1B). This antibody is derived from a patient called patient 101. He was diagnosed with an intermediate-risk AML (no cytogenetic or molecular abnormalities; FAB classification AML-M5) at the age of 49 years. He received two courses of chemotherapy (cytarabine, idarubicine, amsacrine) and one course of consolidation chemotherapy (busulphan, cyclophosphamide) followed by an autologous hematopoietic stem cell transplantation (HSCT), as there was no HLA-matched sibling stem cell donor available. Fourteen months after the first diagnosis his disease relapsed. He obtained complete remission after one cycle of high-dose cytarabine, after which he received a reduced intensity allogeneic HSCT of a matched, unrelated donor (RIST-MUD). Six weeks later he developed acute GvHD of skin, liver and intestine (stage 1; grade II) that responded well to corticosteroid therapy. Given the fact that this patient remained disease free for over 5 years now, despite the high-risk nature of his disease, this patient can be considered to have generated a potent graft versus AML response which was the reason he was selected to search for potent AML-specific antibody responses. B cells were isolated from a phlebotomy product obtained from this patient 38 months post-HSCT, immortalized by introduction of Bcl6 and Bcl-xL as described previously (Kwakkenbos et al., Nat Med 2010) and cultured in 20 or 40 cells/well concentrations. Supernatants of these microcultures were screened for binding to AML cell lines and microcultures specific for AML subcloned in one cell/well concentrations. One of the antibodies identified through this procedure is AT14-013, an IgG1 kappa, highly somatic hypermutated antibody.

[0161] AT14-013 binds specifically to a wide variety of AML cell lines and primary AML cells, covering all AML FAB classifications, as shown in FIG. 2. In FIG. 3, a number of representative examples of AT14-013 binding to Kasumi3, SH-2, Molm13 and THP-1 and to primary leukemic blasts isolated from newly diagnosed AML patients are shown. In addition, AT14-013 binds to other myeloid malignancies such as AML from high-risk myelodysplastic syndrome (MDS/RAEB I/II) or blast crisis chronic myeloid leukemia (CML) and the CML cell line K562 (FIG. 4). AT14-013 did show some binding to granulocytes but did not bind to healthy peripheral blood mononuclear cells (PBMC), bone marrow, thymocytes, hematologic malignancies of the lymphatic lineage or healthy or malignant cells of liver and colon. AT14-013 did bind to cultured melanocytes and melanoma cell lines (FIG. 5A, FIG. 5B, FIG. 5C).

[0162] AT14-013 Induces CDC and ADCC of Target Cells

[0163] AT14-013 can induce complement dependent cytotoxicity and antibody dependent cellular cytotoxicity (FIG. 6) of AML cell lines and primary isolated AML blasts.

[0164] The Target of AT14-013 is a Unique Epitope of CD43

[0165] We then identified the target of AT14-013. Immunoprecipitation (IP) of THP-1 lysate incubated with biotin-labeled sortase-tagged AT14-013 yielded a ˜140 kDa band. The band is specific as it was not seen in the AT10-002 IP of THP1 lysate nor in the Jurkat lysate IP (FIG. 7). Mass-spectometry analysis of the immunoprecipitation band revealed CD43 as the target protein. Three out of three expected intracellular peptides were identified, giving a 7% coverage of the protein, extracellular peptides were not identified since these are heavily glycosylated. CD43 binding by AT14-013 was confirmed by western blot analysis. Briefly, THP-1 and Molm13 lysates were immunoprecipitated with AT14-013 or with the influenza-specific antibody AT10-002. Western blot analysis with mouse-anti-CD43 (clone Mem59) confirmed CD43 as the binding target of AT14-013 (FIG. 8).

[0166] CD43 is widely expressed on healthy and malignant cells. CD43-specific antibodies have been generated and are commercially available, such as DF-T1, 84-3C1, L10 and MEM-59. With these antibodies we confirmed CD43 expression by THP-1 cells (FIG. 9A). The observation that AT14-013 does not bind to non-myeloid cells and the different binding profile of AT14-013 to all sorts of cells and cell lines compared to other CD43 antibodies (FIG. 9B) suggests that AT14-013 recognizes a different CD43 epitope than the other CD43 antibodies. Indeed, when we performed competition experiments, incubating THP-1 cells with commercially available CD43 antibodies and AT14-013, we found that these CD43 antibodies compete with each other for binding to THP-1, but not with AT14-013 (FIG. 9B and FIG. 9B). Of note, CD43 clones L10 and 84-3C1 have been described to compete with each other (L. Borche et al 2005); this is confirmed in our experiment.

[0167] The CD43 protein is a highly glycosylated protein (de Laurentiis et al. 2011). The CD43 antibodies Mem59, DF-T1 and 84-3C1 (but not L10) bind to a sialylated epitope, as after pretreatment of target cells with neuraminidase, which removes all α-N-acetylneuramic acids (sialic acids), binding of these antibodies to CD43 is lost (US2010/0234562A1). In 10 we demonstrate that binding of AT14-013 to THP-1 cells is also lost upon pre-incubation of THP-1 cells with neuraminidase, demonstrating that AT14-013 specifically binds to a sialylated epitope of CD43.

[0168] To more specifically identify the binding epitope of AT14-013, we generated 10 Flag-tagged extracellular-truncated variants of CD43 that were expressed in HEK and THP1 cells. Western blot analysis of lysates of these cells incubated with Mem59 or DF-T1 confirmed binding of these antibodies to a similar epitope between amino acids 59-82 (FIG. 11A and FIG. 11B). We tested AT14-013 binding by immunoprecipitation of THP1 cells transduced with these truncation variants. AT14-013 interacts strongly with variants A-F, to a lesser extent with variant G, and not with variants H-J as shown in the anti-Flag immunoblot of the IP's (FIG. 12A and FIG. 12B). In FIG. 12C we confirmed the AT14-013 IP with an anti C terminal CD43 antibody. In all samples endogenous CD43 was present, whereas there was only truncated CD43 present up to variant G. We therefore conclude that the epitope of AT14-013 lies between amino acids 133 and 184.

Example 2; Binding to AML Blasts

[0169] Material & Methods

[0170] Binding of antibody AT14-013 to different cells was tested using the methodology as described in Example 1 under the heading ‘Generation of AML-specific clone AT14-013’. Patient samples were stained with anti human CD45 (BD) prior to the assay. AML cells were defined as CD45dim. Healthy PBMCs were stained with anti human CD3 (biolegend). Polymorph nuclear cells derived from tonsil were isolated by ficol density gradient.

[0171] Results

[0172] AT14-013 binds specifically to a wide variety of AML cell lines and primary AML cells, covering all AML FAB classifications, as shown in Example 1 and 4. Additionally, we tested the antibody on a broader panel of AML blasts. It showed to bind to all AML blasts tested so far and often better than the commercial anti CD43 antibodies did. Interestingly, the sialic acid independent L10 antibody was binding the least in almost all samples. In addition the antibodies were tested on healthy CD43 expressing T cells and cells derived from tonsil. Here, only the commercial antibodies showed staining. The results are summarized in FIG. 14A and FIG. 14B.

Example 3; ADCC and CDC

[0173] In addition to Example 1 and 6, another ADCC and CDC experiment was performed.

[0174] Material & Methods

[0175] To quantify antibody dependent cell-mediated cytotoxicity (ADCC) and complement dependent cellular cytotoxicity (CDC) of target cells induced by AML-specific antibody AT14-013 we used a FACS-based leukemia cell lysis assay. SH2 cells were incubated with 10 nM Calcein AM (Becton Dickinson) for 30 minutes at 37° C. Calcein labeled cells were then incubated together with antibodies and healthy peripheral blood mononuclear cells (PBMCs; Effector:Target 50:1) for 4 hours or rabbit serum complement for 1 hour at 37° C. FACS calibration beads (Accudrop Fluorescent Beads, BD Biosciences) were added to the cells in a 50/50 ratio after which a standard amount of beads was acquired with FACS. As an equal assay volume was ascertained by the calibration beads, the amount of dead cells was calculated as: 100−((Dapi negative, Calcein AM positive cells in respective treatment/Dapi negative, Calcein AM positive cells in control)×100).

[0176] Results

[0177] AT14-013 Induces CDC and ADCC of Target Cells

[0178] AT14-013 can induce antibody dependent cell mediated cytotoxicity (15A) and induce complement dependent cytotoxicity (15B) of AML cell lines and primary isolated AML blasts.

Example 4; Epitope Mapping: CD43 Truncated Variants

[0179] In addition to Example 1 and FIG. 12A, FIG. 12B, FIG. 12C, the binding epitope of AT14-013 was further investigated.

[0180] Material & Methods

[0181] The same methods as in Example 1 were used. CD43 cDNA was obtained from Geneart (Life Technologies) and adapted to contain a 3×FLAG tag in-frame on either C- or N-terminus (C-terminal to the signal peptide, comprising the first 19 amino acids of CD43). The cDNA was cloned into the pHEF-TIG third-generation lentiviral vector containing an IRES-GFP 3′ of the CD43 cDNA; VSV-G lentiviral particles were produced in HEK293T cells. THP1, MOLM and other cells were transduced with these viruses in the presence of retronectin and sorted for GFP to obtain a pure population of CD43 transduced cells. Truncated CD43 variants were constructed by PCR-cloning of the CD43 C-terminal FLAG-tagged cDNA to contain the signal peptide (AA 1-19) followed by the wild-type full length extracellular sequence (variant A: S20-P400, followed by 3×FLAG: DYKDHDGDYKDHDIDYKDDDDK) or truncated extracellular sequences (variant B-J). B: 31-400; C: 59-400; D: 82-400; E: 112-400; F: 133-400; F2: 148-400; G: 166-400; H: 184-400; I: 202-400; J: 220-400 (the transmembrane domain starts at AA 255). These variants were expressed in THP1 cells by lentiviral transduction and GFP sorted. Sorted cells were lysed and immunoprecipitated with AT14-013 and control as described above. Eluted IP samples were run on SDS-PAGE and immunoblotted with anti-FLAG-HRP (Sigma) to reveal binding.

[0182] Results

[0183] The Target of AT14-013 is a Unique Epitope of CD43

[0184] To more specifically identify the binding epitope of AT14-013, we generated 11 Flag-tagged extracellular-truncated variants of CD43 that were expressed in THP1 cells. We tested AT14-013 binding by immunoprecipitation of THP1 cells transduced with these truncation variants. AT14-013 interacts strongly with variants A-F, to a lesser extent with variant F2, to a lesser extent with variant G, and not with variants H-J as shown in the anti-Flag immunoblot of the IP's (FIG. 16A and FIG. 16B). In FIG. 16b we confirmed the AT14-013 IP with an anti C terminal CD43 antibody. In all samples endogenous CD43 was present, whereas there was only truncated CD43 present up to variant F2. We therefore conclude that the epitope of AT14-013 comprises one or more amino acid residues that are present between amino acids 133 and 165. In view of the fact that AT14-013 interacts to a lesser extent with variant F2 (starting at amino acid position 148 as depicted in FIG. 13), we also conclude that the epitope of AT14-013 at least comprises one or more amino acid residues that are present between amino acids 133 and 147.

Example 5; AT14-013 Inhibits AML Growth In Vivo

[0185] Currently known experimental protocols are for instance described in Miller et al., Blood (2013), Vol. 121, No. 5, e1-e4.

[0186] In order to evaluate the efficacy of AT14-013 against AML in vivo, immunodeficient mice reconstituted with human hematopoietic cells and xenografted with SH-2 cells were treated. Six female NOD.Cg-Prkdc.sup.scid Il2rg.sup.tm1Wjl/SzJ (NSG, The Jackson Laboratory) were humanized by injecting 50 000 CD34.sup.+CD38.sup.− hematopoietic stem cells in the liver of sublethally irradiated newborns (1-5 days). At 8 weeks, mice were bled to evaluate the engraftment of human hematopoietic cells in their blood. Only mice with higher than 20% of human chimerism in the peripheral blood were used in this experiment. Five out of 6 mice met this criterion and were intravenously inoculated at d0 with 10×10.sup.6 SH-2 cells expressing luciferase and GFP. At d14, mice were injected IP with luciferin (150 mg/kg) and the tumor engraftment was assessed by in vivo bioluminescence. Based on this measurement, mice were randomized in 2 groups and subsequently dosed by iv inoculation of AT14-013 or antibody AT10-002 (against influenza, described in WO 2013/081463, as control) (375 μg) twice per week. The bioluminescence was measured every week as described above. On d39, mice were sacrificed by cervical dislocation under deep anesthesia and the organs were exposed and quantified for bioluminescence. Single-cell suspension was obtained for the liver and the bone marrow and the presence of SH-2 GFP+ cells was quantified by FACS. Treatment of mice engrafted with SH-2 AML cells leads to a tumor growth inhibition of 90.3% as measured at the sacrifice by whole body measurement (p<0.001, repeated ANOVA, FIG. 17A). The number of AML cells, measured by the number of photon per minute (cpm) exhibits a strong decrease in all the organs measured (p=0.0011, repeated 2way ANOVA, FIG. 17B). This observation is confirmed by the evaluation of the number of tumor cells by FACS in the bone marrow and the liver (p=0.0017, 2way ANOVA, FIG. 17C).

[0187] Hence, an antibody that is specific for a CD43 peptide according to the present invention is particularly suitable for in vivo treatment or prevention of a myeloproliferative or lymphoproliferative disorder such as AML.

Example 6

[0188] Material & Methods

[0189] Fetal liver, bone marrow and thymus tissue between week 16 and 21 of gestation was obtained from the Human Immune System (HIS) Mouse Facility at the AMC (under Dutch law: Wet Foetaal Weefsel). CD34 enriched mononuclear cell suspensions from tissues were obtained by disrupting whole organs using a Stomacher followed by density gradient centrifugation and magnetic bead separation. CD34 enriched cell suspension of fetal bone marrow was prepared by density gradient centrifugation and magnetic bead separation.

[0190] Binding of antibody AT14-013 to cells from fetal liver, fetal thymus and fetal bone marrow was tested by flow cytometry, using commercially available CD34 (BD, cat. 343516) and CD38 (BD, cat. 303522) antibodies to distinguish the different subsets in these samples.

[0191] Results

[0192] AT14-013 Specifically Binds to an Oncofetal Epitope of CD43

[0193] As described herein before, AT14-013 is a CD43-specific antibody that recognizes a unique, onco-sialylated tumor antigen that is expressed predominantly by AML and MDS blasts. Tumor antigens are either abnormal proteins with tumor-specific expression or aberrantly expressed normal proteins such as onco-fetal antigens, which are antigens that are normally only expressed during ontogeny by fetal tissues. Neoplastic transformation of cells is frequently associated with the expression of oncofetal antigens. We found that the AT14-013 epitope of CD43 was expressed by CD34+ CD38− hematopoietic stem cells obtained from fetal liver and fetal bone marrow, but not by CD34+ CD38+ progenitor cells or CD34− CD38− mature cells obtained from fetal liver and fetal bone marrow (FIG. 18). These results demonstrate that AT14-013 is able to bind to an oncofetal-sialylated epitope of CD43 that in adults is widely expressed by AML and MDS.

Example 7

[0194] AML blasts of donor #101 (the same donor from whom the B cells producing AT14-013 were obtained) were stained with AT14-013 and with antibodies specific for CD34 and CD38 (same procedure as in Example 6), and with an antibody against CD45 (BD, cat 348815) to distinguish the general blast population (CD45 dim) from healthy cells in the bone marrow and analyzed by flow cytometry (FIG. 19). This shows that AT14-013 binds leukemic blasts of the patient it was found in. AT14-013 binds CD34+CD38− blasts that include the leukemic stem cells.

[0195] It is therefore concluded that antibody AT14-013 reacts with autologous leukemic stem cells, which makes AT14-013 particularly suitable for treatment or prevention of myeloproliferative or lymphoproliferative disorders because it also targets the leukemic stem cells, which are known to be more therapy resistant and often responsible for relapse of disease after treatment.

[0196] From this it follows that another antibody that is specific for a CD43 peptide according to the invention, such as an antibody that competes with antibody AT14-013 for binding to CD43, is also particularly suitable for treatment or prevention of myeloproliferative or lymphoproliferative disorders.

REFERENCES

[0197] Bennett, J. M. et al., 1976. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. British Journal of Haematology, 33(4), pp. 451-458. [0198] Borche, L. et al., 2005. CD43 monoclonal antibodies recognize the large sialoglycoprotein of human leukocytes. European Journal of Immunology, 17(10), pp 1523-1526 [0199] European Patent No. 1974017 [0200] Hanly et al. Review of polyclonal antibody production procedures in mammals and poultry. ILAR Journal (1995); Vol. 37, Number 3: 93-118 [0201] International patent application No. WO 2015/093949 [0202] International patent application No. WO 2006/121240 [0203] International patent application No. WO 2007/146172 [0204] Kim et al. Characterization of two novel mAbs recognizing different epitopes on CD43. Immune Network (2014). Vol. 14, No. 3: 164-170 [0205] Kwakkenbos M J et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med. 2010. 16(1):123-8. [0206] de Laurentiis, A. et al., 2011. Mass Spectrometry-Based Identification Of The Tumor Antigen UN1 as the Transmembrane CD43 Sialoglycoprotein. Molecular & Cellular Proteomics, 10(5), pp. M111.007898-M111.007898 [0207] Malcovati, L. et al., 2013. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 122(17), pp. 2943-2964 [0208] Miller et al., Blood (2013), Vol. 121, No. 5, e1-e4 [0209] Schmid K, Hediger M A, Brossmer R, et al. Amino acid sequence of human plasma galactoglycoprotein: identity with the extracellular region of CD43 (sialophorin). Proc. Natl. Acad. Sci. U.S.A. 1992; 89(2):663-667 [0210] Shelley et al. Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndrome. Proc. Natl. Acad. Sci. U.S.A. 1989; Vol. 86: 2819-2823 [0211] Swerdlow S. H. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, 2008. ISBN: 978-92-832-2431-0 [0212] Tuccillo et al. Cancer-associated CD43 glycoforms as target of immunotherapy. Mol. Cancer ther. (2014a) 13(3): 752-762 [0213] Tuccillo et al. Aberrant glycosylation as biomarker for cancer: focus on CD43. BioMed research International (2014b) Article ID 742831, 13 pages. http://dx.doi.org/10.1155/2014/742831 [0214] U.S. Pat. No. 9,005,974